Human Immunology News Volume 9.46 | Nov 23 2021

    By
    Justin.choi
    -
    0
    38







    2021-11-23 | HIN 9.45


    Human Immunology News by STEMCELL Technologies
    Vol. 9.45 – 23 November, 2021
    TOP STORY

    Type I Interferon Activates MHC Class I-Dressed CD11b+ Conventional Dendritic Cells to Promote Protective Anti-Tumor CD8+ T Cell Immunity

    Transcriptional profiling of intra-tumoral dendritic cells (DCs) within regressor tumors revealed an activation state of CD11b+ conventional DCs characterized by expression of interferon-stimulated genes.
    [Immunity]

    AbstractGraphical Abstract
    Request a copy of the COVID-19 wallchart.
    PUBLICATIONSRanked by the impact factor of the journal

    Discovery of Anti-Inflammatory Physiological Peptides That Promote Tissue Repair by Reinforcing Epithelial Barrier Formation

    Investigators found tight junction-inducing peptides in mice and humans that corresponded to 35 to 42 residue peptides of the C terminus of alpha 1-antitrypsin, an acute-phase anti-inflammatory protein.
    [Science Advances]

    Full Article

    Deubiquitination of Proteasome Subunits by OTULIN Regulates Type I IFN Production

    Scientists found a remarkable activation of type I interferon (IFN-I) signaling in whole blood, peripheral blood mononuclear cells, monocytes, and serum from patients with OTULIN deficiency.
    [Science Advances]

    Full Article

    Desmoplakin and Periplakin Genetically and Functionally Contribute to Eosinophilic Esophagitis

    A series of rare, heterozygous, missense variants were identified in the genes encoding the desmosome-associated proteins DSP and PPL in 21% of the multiplex families.
    [Nature Communications]

    Full Article

    A High OXPHOS CD8 T Cell Subset Is Predictive of Immunotherapy Resistance in Melanoma Patients

    Using single-cell transcriptomics, researchers discovered a unique CD8 T cell blood/tumor-shared subpopulation in melanoma patients with high levels of oxidative phosphorylation (OXPHOS), the ectonucleotidases CD38 and CD39, and both exhaustion and cytotoxicity markers.
    [Journal of Experimental Medicine]

    Abstract

    Desmosterol Suppresses Macrophage Inflammasome Activation and Protects against Vascular Inflammation and Atherosclerosis

    Investigators reported that desmosterol, the most abundant cholesterol biosynthetic intermediate in human coronary artery lesions, played an essential role during atherogenesis, serving as a key molecule integrating cholesterol homeostasis and immune responses in macrophages.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    B7-H3 Suppresses Anti-Tumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression

    Transcriptome analysis revealed that B7-H3 was highly expressed in PD-L1-low, non-immunoreactive high-grade serous ovarian cancer tumors, and its expression negatively correlated with an IFNγ signature, which reflected the tumor immune-reactivity.
    [Cancer Immunology Research]

    Abstract

    Three-Dimensional Printing of Bioceramic-Induced Macrophage Exosomes: Immunomodulation and Osteogenesis/Angiogenesis

    3D printed macrophage exosomes scaffolds, exhibiting a predefined structure and persistent release of exosomes, displayed distinct immunomodulatory effects and improved osteogenesis/angiogenesis.
    [NPG Asia Materials]

    Full Article

    Monocytes Secrete CXCL7 to Promote Breast Cancer Progression

    To identify key immune players in the tumor microenvironment, investigators applied highly invasive MDA-MB-231 breast cancer cell lines to co-culture with human monocyte THP-1 cells and identified CXCL7 by cytokine array as one of the increasingly secreted cytokines by THP-1 cells.
    [Cell Death & Disease]

    Full Article

    PD-L1 Expression on Circulating Tumor Cells and Platelets in Patients with Metastatic Breast Cancer

    Whole blood was collected at serial timepoints from metastatic breast cancer patients and healthy donors for circulating tumor cell and platelet PD-L1 analysis with a phycoerythrin-labeled anti-human PD-L1 monoclonal antibody using the CellSearch® assay.
    [PLoS One]

    Full Article
    Request your free copy of the 'Human Immune Cytokines' Wallchart
    REVIEWS

    Human Immune Diversity: From Evolution to Modernity

    Scientists review the current state of play in the field, identify the key unknowns in the causality of immune variation, and identify the multidisciplinary pathways toward an improved understanding.
    [Nature Immunology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Rain Therapeutics Doses First Patient in Phase II Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

    Rain Therapeutics, Inc. announced that the first patient has been dosed in the multicenter, single arm, open-label, Phase II basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors.
    [Rain Therapeutics, Inc.]

    Press Release

    MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase II Trial of MYMD-1 for Extending Healthy Lifespan

    MyMD Pharmaceuticals, Inc. announced that it has received US FDA clearance of its Investigational New Drug (IND) application for the Phase II trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan.
    [MyMD Pharmaceuticals, Inc.]

    Press Release
    FEATURED EVENT

    Australian Neuroscience Society (ANS)

    December 6 – 8, 2021
    Melbourne, Victoria, Australia

    > See All Events

    JOB OPPORTUNITIES

    PhD Positions – Cell Surface Glycome

    The University of British Columbia – Vancouver, British Columbia, Canada

    Scientific Researcher – Cancer Immunology

    Genentech – San Francisco, California, United States

    Research Scientist – Immunology

    AbCellera – Vancouver, British Columbia, Canada

    Research Associate – Cancer, Immunity, and Stem Cell Biology

    UC San Diego Health – La Jolla, California, United States

    Scientist – Immune System-Tumor Interactions

    Oregon Health & Science University – Portland, Oregon, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter